Perspective · 29 Aug 2025
Conference abstract
Harmonization in BABE studies: Regulatory aspects
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
B ioavailability and Bioequivalence studies play a major role in the drug development especially for both new drug products and their generic equivalents. Several approaches to assess Bioequivalence and each regulatory authority has its own regulations for conducting BA/BE studies before approving generic products for marketing. Thus, there is a greater need to harmonize the regulatory environment globally for bioequivalence assessment practically so that the drug product marketed in different parts and regions of the world. The assessment of BE of different drug products is based on the fundamental assumption that two products are equivalent when the rate and extent of absorption of the test/generic drug does not show a significant difference from the rate and extent of absorption of the reference/ brand drug under similar experimental conditions. The approach of one size-to fit -all has begun to dissipate in recent years authorities from Europe, Canada, and United States, narrower BE limits have been proposed for drugs with narrow therapeutic windows. WHO has made remarkable progress in drug interchangeability. Apart from ICH, European and Asian organizations are actively involved in harmonization efforts for assessing of BE and improving the quality of pharmaceutical products globally. Global harmonization for regulatory requirements may be promoted by a better understanding of mentioned various approaches for bioequivalence assessment from different regulatory authorities to guarantee the safety and efficacy of the drugs and there by protecting the end users and consumers.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 25 Sep 2017
Roadmap to pharmaceutical regulatory harmonization in Pakistan
Conference abstract · 3 Aug 2015
Beyond harmonization: Regulatory innovation for the next generation of drug development
Review article · 2015
Regulatory Need: Harmonized PIC/S GMP, Its Overview and Comparison with WHO GMP
Conference abstract · 12 Nov 2013
The necessity of establishing a harmonized international regulatory system for the control of APIs
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “T.S. Jaishankar”
